The tool that makes this possible is the beam profiler, which captures a two-dimensional plot of the intensity of a laser beam. Although many people might imagine that the power density of a laser ...

BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...

What risks are associated with the safety profile of Beam's therapies? The safety profile of Beam's base editing therapies remains a critical concern for investors and regulators alike.

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results. Cathie Wood, CEO of ARK Invest, is doubling ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...